Abstract：
BACKGROUND: The availability of HIV antiretroviral therapy (ART) has been associated with the development of transmitted drug resistance-associated mutations (TDRM). TDRM can compromise treatment effectiveness in patients initiating ART and the prevalence can vary in different clinical settings. In this study, we investigated the proportion of TDRM in treatment-naïve, recently infected HIV-positive individuals sampled from four urban locations across Asia between 2007-2010.
METHODS: Patients enrolled in the TREAT Asia Studies to Evaluate Resistance - Surveillance Study (TASER-S) were genotyped prior to ART initiation, with resulting resistance mutations analysed according to the WHO 2009 list.
RESULTS: Proportions of TDRM from recently infected individuals from TASER-S ranged from 0% to 8.7% - Hong Kong: 3/88 (3.4%, 95% CI (0.71%-9.64%)); Thailand: Bangkok: 13/277 (4.7%, 95% CI (2.5%-7.9%)), Chiang Mai: 0/17 (0%, 97.5% CI (0%-19.5%)); and the Philippines: 6/69 (8.7%, 95% CI (3.3%-18.0%)). There was no significant increase in TDRM over time across all four clinical settings.
CONCLUSIONS: The observed proportion of TDRM in TASER-S patients from Hong Kong, Thailand and the Philippines was low to moderate during the study period. Regular monitoring of TDRM should be encouraged, especially with the scale-up of ART at higher CD4 levels.
METHODS: Patients enrolled in the TREAT Asia Studies to Evaluate Resistance - Surveillance Study (TASER-S) were genotyped prior to ART initiation, with resulting resistance mutations analysed according to the WHO 2009 list.
RESULTS: Proportions of TDRM from recently infected individuals from TASER-S ranged from 0% to 8.7% - Hong Kong: 3/88 (3.4%, 95% CI (0.71%-9.64%)); Thailand: Bangkok: 13/277 (4.7%, 95% CI (2.5%-7.9%)), Chiang Mai: 0/17 (0%, 97.5% CI (0%-19.5%)); and the Philippines: 6/69 (8.7%, 95% CI (3.3%-18.0%)). There was no significant increase in TDRM over time across all four clinical settings.
CONCLUSIONS: The observed proportion of TDRM in TASER-S patients from Hong Kong, Thailand and the Philippines was low to moderate during the study period. Regular monitoring of TDRM should be encouraged, especially with the scale-up of ART at higher CD4 levels.
摘要：
背景：HIV抗逆转录病毒治疗（ART）的可用性与传播的耐药性相关突变（TDRM）的发展有关。TDRM可能会损害开始ART的患者的治疗有效性，并且患病率在不同的临床环境中可能会有所不同。在这项研究中,我们调查了TDRM在幼稚治疗中的比例，2007年至2010年期间，从亚洲四个城市地区抽取了最近感染的HIV阳性个体。
方法：参加亚洲治疗研究以评估耐药性-监测研究（TASER-S）的患者在开始ART之前进行基因分型，根据WHO2009年清单分析产生的耐药突变。
结果：来自TASER-S的最近感染个体的TDRM比例从0%到8.7%不等-香港：3/88（3.4%，95%CI（0.71%-9.64%）；泰国：曼谷：13/277（4.7%，95%CI（2.5%-7.9%），清迈：0/17（0%，97.5%CI（0%-19.5%）；菲律宾：6/69（8.7%，95%CI（3.3%-18.0%））。在所有四种临床设置中,TDRM随时间没有显著增加。
结论：来自香港的TASER-S患者中TDRM的观察比例，在研究期间，泰国和菲律宾的情况低到中等。应鼓励定期监测TDRM，特别是随着ART在更高的CD4水平上的扩大。
方法：参加亚洲治疗研究以评估耐药性-监测研究（TASER-S）的患者在开始ART之前进行基因分型，根据WHO2009年清单分析产生的耐药突变。
结果：来自TASER-S的最近感染个体的TDRM比例从0%到8.7%不等-香港：3/88（3.4%，95%CI（0.71%-9.64%）；泰国：曼谷：13/277（4.7%，95%CI（2.5%-7.9%），清迈：0/17（0%，97.5%CI（0%-19.5%）；菲律宾：6/69（8.7%，95%CI（3.3%-18.0%））。在所有四种临床设置中,TDRM随时间没有显著增加。
结论：来自香港的TASER-S患者中TDRM的观察比例，在研究期间，泰国和菲律宾的情况低到中等。应鼓励定期监测TDRM，特别是随着ART在更高的CD4水平上的扩大。
